Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in multiple investor conferences during September 2025.

The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, CCO John Northcott, and CBO Jason Kantor, will attend five major healthcare conferences: Wells Fargo, H.C. Wainwright, RW Baird, Morgan Stanley, and Stifel Virtual Immunology Forum. All presentations will be webcast live and available for 30 days through Nurix's website.

Nurix Therapeutics (Nasdaq: NRIX) reported significant progress in Q2 2025, highlighted by positive clinical developments and strategic collaborations. The company presented updated data for bexobrutideg (NX-5948), showing an impressive 80.9% objective response rate in r/r CLL patients. Nurix secured a $15M license fee from Sanofi's STAT6 collaboration extension and received FDA clearance for IRAK4 degrader GS-6791/NX-0479.

Financial highlights include Q2 2025 revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. R&D expenses increased to $78.1M from $48.9M, while net loss improved to $43.5M ($0.52 per share) compared to $44.5M ($0.71 per share) in Q2 2024.

Nurix Therapeutics (Nasdaq: NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation from the European Medicines Agency for treating lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).

The designation provides significant benefits including 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees. Bexobrutideg, an oral BTK degrader, is currently in Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies.

The drug has already received multiple regulatory designations, including FDA Fast Track for WM and CLL/SLL treatment, and EMA PRIME designation for CLL/SLL treatment, demonstrating strong regulatory momentum.

Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has granted inducement awards to 17 new employees on June 10, 2025. The awards include stock options for 97,400 shares with an exercise price of $12.79 per share and restricted stock units (RSUs) for 66,750 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly. RSUs will also vest over four years, with 25% vesting after one year and the remainder vesting quarterly. The grants were made under Nurix's 2024 Equity Inducement Plan and approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).

Nurix Therapeutics announced positive clinical data for bexobrutideg (NX-5948) in treating relapsed/refractory CLL and WM patients. The Phase 1a/b trial showed impressive results with an 80.9% overall response rate in CLL patients and 84.2% in WM patients. The drug demonstrated durable responses, including a complete response in one CLL patient after two years of treatment. The study included heavily pretreated patients with a median of four prior therapies for CLL and three for WM. Bexobrutideg was well-tolerated across all doses, with no new safety concerns and notably no new onset atrial fibrillation. The company plans to initiate pivotal trials in 2025, positioning bexobrutideg as a potential breakthrough treatment for patients with limited therapeutic options.

Nurix Therapeutics (NRIX) announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from their ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). The data will be presented at the European Hematology Association Congress in Milan. Two poster presentations will showcase the drug's performance: one focusing on its efficacy in relapsed refractory CLL, presented by Dr. Talha Munir, and another highlighting its clinical activity and safety in Waldenström macroglobulinemia patients, presented by Dr. Dima El-Sharkawi. The webcast will be accessible through Nurix's website, with dial-in options available for U.S. and international participants. A replay will be archived for approximately 30 days after the event.

Nurix Therapeutics (NRIX) announced that Sanofi has exercised its option to exclusively license Nurix's STAT6 program, including NX-3911, an oral STAT6 degrader. The license extension triggers a $15M payment to Nurix, bringing total collaboration payments to $127M. Nurix remains eligible for up to $465M in additional milestones plus royalties and retains U.S. co-development/co-promotion rights. NX-3911, developed using Nurix's DEL-AI platform, targets STAT6, a key factor in type 2 inflammation driving conditions like atopic dermatitis and asthma. The drug has shown promising preclinical results, achieving complete STAT6 degradation and demonstrating efficacy comparable to STAT6 gene knockout in animal models. This marks Sanofi's second license extension of a Nurix autoimmune program in 90 days, validating Nurix's drug discovery platform.

Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.

Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.

The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.